| 朱 梅,吕 姣,李艳芳.rhu-TNF腔内治疗恶性胸腔积液的疗效与可能机制探讨[J].肿瘤学杂志,2016,22(8):658-662. |
| rhu-TNF腔内治疗恶性胸腔积液的疗效与可能机制探讨 |
| Efficacy of Malignant Pleural Effusion Treated by Intrapleural Perfusion with Recombinant Human Mutant Tumor Necrosis Factor and Its Possible Mechanism |
| 投稿时间：2016-02-23 |
| DOI：10.11735/j.issn.1671-170X.2016.08.B010 |
|
 |
| 中文关键词: 恶性胸腔积液 注射用重组人改构肿瘤坏死因子 Bcl-2 Bax |
| 英文关键词:malignant pleural effusion rhu-TNF Bcl-2 Bax |
| 基金项目:国家十二五科技支撑计划资助项目（2013BAI06B04H008） |
|
| 摘要点击次数: 2018 |
| 全文下载次数: 543 |
| 中文摘要: |
| 摘 要：［目的］ 研究注射用重组人改构肿瘤坏死因子(rhu-TNF)腔内注射治疗恶性胸腔积液的疗效并探讨其可能机制。［方法］ 将60例恶性胸腔积液患者随机分为对照组（29例）和观察组（31例），对照组给予顺铂(DDP)治疗，观察组在对照组基础上给予rhu-TNF。收集并对比治疗前后各组胸水的Bcl-2 mRNA和Bax mRNA表达，以及治疗后的疗效(RR)、临床获益反应(CBR)、不良反应、疾病进展时间(TTP)。［结果］ 治疗前，两组Bcl-2 mRNA和Bax mRNA的表达无显著差异(P>0.05)，治疗后，两组Bcl-2 mRNA均降低(P<0.05)，Bax mRNA的表达增高(P<0.05)；与对照组比，观察组的Bcl-2 mRNA明显降低(P<0.05)，Bax mRNA的表达明显增高(P<0.05)。对照组RR、CBR分别为 41.38%和48.28%，观察组RR、CBR分别为70.97%和77.41%，两组间差异有统计学意义(P<0.05)。随访3~12个月，对照组TTP为5.1个月，观察组TTP为7.1个月，差异有统计学意义(P<0.05)。两组不良反应无显著差异。［结论］ rhu-TNF治疗恶性胸腔积液的机理之一在于降低胸腔脱落细胞Bcl-2表达，升高Bax表达，促进肿瘤细胞凋亡，且无明显的不良反应。 |
| 英文摘要: |
| Abstract：［Objective］ To explore the clinical effect and the possible mechanism of recombinant human mutant tumor necrosis factor(rhu-TNF) in the treatment of malignant pleural effusion．［Methods］ 60 cases with malignant pleural effusion were randomly divided into 2 groups， 29 cases in control group who accepted cisplatin(DDP) and 31 cases in observation group who accepted DDP combined with rhu-TNF. Bcl-2 mRNA and Bax mRNA were detected before and after treatment. The effective rate，responding time and adverse reaction were observed in 2 groups after treatment. ［Results］ Before treatment， Bcl-2 mRNA and Bax mRNA expression had no significant difference in 2 groups. After treatment， expression of Bcl-2 mRNA decreased， expression of Bax mRNA increased in 2 groups. Compared with the control group， expression of Bcl-2 mRNA decreased， expression of Bax mRNA increased in the observation group significantly(P<0.05). The RR and CBR were 41.38% and 48.28% in control group， while 70.97% and 77.41% in observation group， respectively. TTP were 5.1 and 7.1 months in the control group and the observation group， respectively. Compared with the control group， the RR，CBR and TTP increased in the observation group significantly(P<0.05).［Conclusion］ The rhu-TNF is a valid option for the treatment of malignant pleural effusion by decreasing Bcl-2 expression and increasing Bax expression， with a good tolerability． |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |